409 related articles for article (PubMed ID: 26406401)
21. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
[TBL] [Abstract][Full Text] [Related]
22. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of prognostic factors in 68 patients with cancer of unknown primary site].
Kou XG; Liang DL; Zhang QQ; Li XR; Zhao YZ; Gu JF; Lu P
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):783-6. PubMed ID: 22335913
[TBL] [Abstract][Full Text] [Related]
24. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
25. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
26. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
27. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320
[TBL] [Abstract][Full Text] [Related]
29. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
30. Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients.
Fei ZH; Yao CY; Yang XL; Huang XE; Ma SL
Asian Pac J Cancer Prev; 2013; 14(9):5293-9. PubMed ID: 24175816
[TBL] [Abstract][Full Text] [Related]
31. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
32. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Wang W; Huang L; Jin JY; Jolly S; Zang Y; Wu H; Yan L; Pi W; Li L; Mellor AL; Kong FS
Cancer Res; 2018 Feb; 78(3):809-816. PubMed ID: 29118088
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
34. Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?
Wei S; Asamura H; Kawachi R; Sakurai H; Watanabe S
J Thorac Oncol; 2011 Feb; 6(2):310-8. PubMed ID: 21206387
[TBL] [Abstract][Full Text] [Related]
35. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.
Neri S; Ishii G; Taira T; Hishida T; Yoshida J; Nishimura M; Nagai K; Ochiai A
Ann Surg Oncol; 2012 Nov; 19(12):3953-62. PubMed ID: 22669451
[TBL] [Abstract][Full Text] [Related]
36. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
37. Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC.
Sanders KJ; Hendriks LE; Troost EG; Bootsma GP; Houben RM; Schols AM; Dingemans AM
J Thorac Oncol; 2016 Jun; 11(6):873-9. PubMed ID: 26940529
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
[TBL] [Abstract][Full Text] [Related]
39. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
40. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.
Morgensztern D; Waqar S; Subramanian J; Gao F; Govindan R
J Thorac Oncol; 2009 Dec; 4(12):1524-9. PubMed ID: 19752759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
